文献速递膀胱癌与上尿路尿路上皮癌

阿维鲁单抗一线维持治疗晚期尿路上皮癌:患者报告结局与质量调整无毒性症状时间的长期分析

Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial.
PubMed 文献 · Eur Urol Oncol · 2025-05-02

JAVELIN Bladder 100试验的长期分析显示,一线铂类化疗后未进展的晚期尿路上皮癌患者中,阿维鲁单抗维持联合BSC组患者报告结局完成率>80%,FBlSI-18和EQ-5D-5L评分在24个月内稳定;Q-TWiST分析示阿维鲁单抗组平均18.46个月优于BSC单用组15.13个月,相对改善22%。

要点

  • 阿维鲁单抗维持治疗期间患者报告结局完成率>80%,健康相关生活质量稳定。
  • FBlSI-18总分和EQ-5D-5L指数评分在24个月治疗中无临床重要变化。
  • Q-TWiST平均18.46个月 vs 15.13个月,相对改善22%。

核心结论

  • 阿维鲁单抗一线维持治疗患者健康相关生活质量得以保持,癌症相关症状得到控制,毒性可管理。
  • 结果进一步支持阿维鲁单抗作为铂类化疗后未进展晚期尿路上皮癌的推荐治疗。

研究设计与样本

  • JAVELIN Bladder 100试验的长期患者报告结局分析及Q-TWiST事后分析。
  • 阿维鲁单抗联合BSC组总体n=350,其中治疗≥12个月亚组n=118。

主要发现

  • 总体阿维鲁单抗组和治疗≥12个月亚组中,治疗期间PRO评估完成率均>80%。
  • FBlSI-18总分和EQ-5D-5L指数评分在24个月治疗中保持稳定,较基线无临床重要变化。
  • Q-TWiST均值阿维鲁单抗联合BSC组为18.46个月,BSC单用组为15.13个月,相对改善22%。

关键数值与推荐

  • PRO评估工具为FBlSI-18和EQ-5D-5L。
  • Q-TWiST计算为三个健康状态的平均时间效用加权总和:进展前全因3/4级毒性时间、无3/4级毒性或进展症状时间、进展后时间。

临床怎么用

  • 对于铂类化疗后未进展的晚期尿路上皮癌患者,阿维鲁单抗一线维持治疗可保持生活质量并控制症状。
  • 长期治疗中患者报告结局完成率高,支持临床持续监测和患者管理。

局限性

  • 试验为开放标签设计。
  • 后期周期患者数量较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: In JAVELIN Bladder 100, avelumab first-line maintenance plus best supportive care (BSC) significantly prolonged overall survival versus BSC alone, with no detrimental impact on quality of life (QOL), in patients with advanced urothelial carcinoma without progression following first-line platinum-based chemotherapy. We report long-term analyses of patient-reported outcomes (PROs) in patients treated with avelumab (any duration or ≥12 mo) and a post hoc analysis comparing quality-adjusted time without symptoms or toxicity (Q-TWiST) between arms. METHODS: PROs were assessed using National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBlSI-18) and EuroQol 5-level EQ-5D (EQ-5D-5L). Q-TWiST was calculated as the utility-weighted sum of mean time in three health states: time with all-cause grade 3/4 toxicity prior to progression, time without grade 3/4 toxicity or symptoms of progression, and time after progression. KEY FINDINGS AND LIMITATIONS: In the overall avelumab plus BSC arm (n = 350) and the subgroup treated for ≥12 mo (n = 118), completion rates for PRO assessments during treatment were >80%. FBlSI-18 total and EQ-5D-5L index scores remained stable throughout 24 mo of treatment, with no clinically important changes from baseline. The mean Q-TWiST was 18.46 mo with avelumab plus BSC versus 15.13 mo with BSC alone (22% relative improvement). Limitations include open-label trial design and small patient numbers at later cycles. CONCLUSIONS AND CLINICAL IMPLICATIONS: Patients receiving avelumab had preserved health-related QOL and control of cancer-related symptoms with manageable toxicity, further supporting avelumab first-line maintenance as the recommended treatment for advanced urothelial carcinoma not progressed after platinum-based chemotherapy.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Grivas P, Aragon-Ching JB, Bellmunt J, et al. Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial. Eur Urol Oncol. 2025. PMID: 40318950. doi:10.1016/j.euo.2025.04.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。